David Bejker
Direttore/Membro del Consiglio presso ABLIVA AB
Profilo
David Bejker currently works at Affibody AB, as Chief Executive Officer & Director, Affibody Medical AB, as Chief Executive Officer from 2018, Abliva AB, as Independent Director from 2017, Amylonix AB, as Director, and Disruptive Pharma Holding AB, as Director.
Mr. Bejker also formerly worked at Nexstim Oyj, as Deputy Director, LIDDS AB, as Independent Director, and HealthCap AB, as Principal.
Mr. Bejker received his graduate degree from Stockholm School of Economics.
Posizioni attive di David Bejker
| Società | Posizione | Inizio |
|---|---|---|
| ABLIVA AB | Direttore/Membro del Consiglio | 27/04/2017 |
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Amministratore Delegato | 02/11/2009 |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Amministratore Delegato | 01/12/2018 |
Amylonix AB
 Amylonix AB Pharmaceuticals: MajorHealth Technology Amylonix AB develops pharmaceuticals focused on the neurodegenerative area. Amylonix AB is based in Johanneshov, Sweden. It was founded in 2018 by Karin Marianne Hansson, who has been the CEO since 2018. | Direttore/Membro del Consiglio | - |
| Disruptive Pharma Holding AB | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di David Bejker
| Società | Posizione | Fine |
|---|---|---|
| NEXSTIM PLC | Corporate Officer/Principal | - |
| LIDDS AB | Direttore/Membro del Consiglio | - |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Corporate Officer/Principal | - |
Formazione di David Bejker
| Stockholm School of Economics | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ABLIVA AB | Health Technology |
| NEXSTIM PLC | Health Technology |
| LIDDS AB | Health Technology |
| Aziende private | 5 |
|---|---|
Affibody AB
Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Commercial Services |
HealthCap AB
HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Finance |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
Amylonix AB
Amylonix AB Pharmaceuticals: MajorHealth Technology Amylonix AB develops pharmaceuticals focused on the neurodegenerative area. Amylonix AB is based in Johanneshov, Sweden. It was founded in 2018 by Karin Marianne Hansson, who has been the CEO since 2018. | Health Technology |
| Disruptive Pharma Holding AB |
- Borsa valori
- Insiders
- David Bejker
